Karpouzas GA, Ormseth SR, Hernandez E, et al. - This study was undertaken to investigate if anti-Beta-2-Glycoprotein-I (anti-β2GPI) IgA antibodies associate with progression of coronary atherosclerosis and cardiovascular disease (CVD) events in rheumatoid arthritis (RA). Researchers included a total of 150 patients who had undergone plaque evaluation (total, non-calcified, mixed, and calcified) with coronary computed tomography angiography; 101 were re-imaged within 6.9±0.3 years to assess progression. This study’s findings revealed that the anti-β2GPI IgA addition to clinical risk models improved prediction accuracy of CAC, plaque progression, and transition to extensive/obstructive disease. As per the outcomes, they correlated with new high-risk mixed plaques and delayed healing to calcified lesions. The results indicated that the anti-β2GPI IgA further modified the impact of inflammation on plaque progression and CVD events.